Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
Radius Health, Inc. (RDUS)
Sector: Healthcare; Industry: Drug Manufacturers—Specialty & Generic

Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2017-05-12 BIOTECH GROWTH N V 10%-Owner Buy 15,000 $34.00 $509,996 No
2017-05-09 BIOTECH GROWTH N V 10%-Owner Buy 50,000 $35.93 $1,796,480 No
2017-05-08 BIOTECH GROWTH N V 10%-Owner Buy 43,400 $35.57 $1,543,912 No
2017-05-02 BIOTECH GROWTH N V 10%-Owner Buy 75,000 $33.91 $2,542,920 No
2017-05-01 BIOTECH GROWTH N V 10%-Owner Buy 150,000 $35.39 $5,308,605 No
2017-03-21 BIOTECH GROWTH N V 10%-Owner Buy 50,000 $35.83 $1,791,625 No
2017-03-17 BIOTECH GROWTH N V 10%-Owner Buy 30,000 $38.41 $1,152,249 No
2017-03-15 BIOTECH GROWTH N V 10%-Owner Buy 61,721 $39.97 $2,466,871 No
2017-03-10 BIOTECH GROWTH N V 10%-Owner Buy 38,279 $39.17 $1,499,285 No
2016-01-25 Fitzpatrick Lorraine A. Chief Medical Officer Buy 200 $49.28 $9,856 No
2016-01-22 BIOTECH GROWTH N V 10%-Owner Buy 38,259 $31.67 $1,211,502 No
2016-01-13 BIOTECH GROWTH N V 10%-Owner Buy 50,000 $39.90 $1,994,885 No
2015-11-23 Ward Robert President & CEO Sell 25,000 $62.77 $1,569,125 Yes
2015-11-12 Hattersley Gary Chief Scientific Officer Sell 5,683 $75.00 $426,225 Yes
2015-11-03 Hattersley Gary Chief Scientific Officer Sell 13,333 $70.00 $933,310 Yes
2015-10-23 Hattersley Gary Chief Scientific Officer Sell 11,302 $65.00 $734,630 Yes
2015-10-21 Hattersley Gary Chief Scientific Officer Sell 1,501 $65.36 $98,105 Yes
2015-09-14 Snow David P. Chief Commercial Officer Buy 6,000 $69.79 $418,740 No
2015-08-31 Purandare Dinesh SVP Global Oncology/Commercial Buy 200 $62.20 $12,440 No
2015-08-21 BIOTECH GROWTH N V 10%-Owner Buy 100,000 $64.00 $6,400,030 No
2015-08-17 Graves Kurt Director Sell 22,694 $70.00 $1,588,580 Yes
2015-08-10 Graves Kurt Director Sell 2,306 $70.00 $161,420 Yes
2015-07-23 BIOTECH GROWTH N V 10%-Owner Buy 250,000 $74.00 $18,500,000 No
2015-07-06 Graves Kurt Director Sell 25,000 $69.48 $1,736,907 Yes
2015-06-18 Graves Kurt Director Sell 25,000 $55.05 $1,376,250 Yes
2015-05-01 BIOTECH GROWTH N V 10%-Owner Buy 50,000 $36.46 $1,822,965 No
2015-04-29 BIOTECH GROWTH N V 10%-Owner Buy 50,000 $36.23 $1,811,580 No
2015-04-28 BIOTECH GROWTH N V 10%-Owner Buy 50,000 $36.59 $1,829,275 No
2015-04-27 BIOTECH GROWTH N V 10%-Owner Buy 50,000 $38.38 $1,919,010 No
2015-03-06 BIOTECH GROWTH N V 10%-Owner Buy 75,000 $47.08 $3,531,128 No

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.

Insider Smart

CARNIVAL CORP (CCL) - Cruislines $CCL $NCLH $RCL took a huge beat due to the pandemic, concerns of bankruptcy were raised. Among the three dominating companies in the industry, $CCL is the first one bought by insiders, such a bold move would definitely boost investor confidence.